论文部分内容阅读
目的 评价乳腺浸润性导管癌的分型及分级与预后的关系。方法 将343例乳腺浸润导管癌的石蜡HE切片重新阅片,对每例切片分别按国内和国际标准(WHO分类)进行病理组织学分型及分级,比较它们与预后的关系。结果 以国内标准划分单纯癌208例(606%),硬癌5例(15%),髓样癌130例(379%),其预后无显著性差异。这些病例按WHO分类均归为浸润性导管癌。以Bloom-Richardson和Elston分级法进行组织学分级,结果Ⅰ级48例,Ⅱ级185例,Ⅲ级110例,其5年生存率分别为875%(42例),730%(135例),500%(55例)。Ⅰ、Ⅱ、Ⅲ的5年生存率有显著性差异。结论 乳腺非特殊型浸润性导管癌应按WHO分类诊断并进行分级。
Objective To evaluate the relationship between classification and grade of breast infiltrating ductal carcinoma and its prognosis. Methods 343 paraffin-embedded HE specimens of breast infiltrating ductal carcinoma were read again. Histopathological classification and grading of each specimen were performed according to national and international standards (WHO classification). Their relationship with prognosis was compared. Results According to the national standard, 208 cases (606%) were diagnosed as simple cancer, 5 cases (15%) as hard cancer, and 130 cases (379%) as medullary carcinoma. There was no significant difference in prognosis. These cases were classified as invasive ductal carcinoma according to the WHO classification. The histological grades were graded by Bloom-Richardson and Elston. The results were 48 grade I, 185 grade II, and 110 grade III. The five-year survival rates were 875% (42 cases) and 730% (135 cases). 500% (55 cases). The 5-year survival rates of I, II, and III were significantly different. Conclusion Non-specific invasive ductal breast cancer should be diagnosed and graded according to the WHO classification.